Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.1 USD | +2.00% | +2.62% | -34.53% |
May. 14 | Transcript : Syros Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 14, 2024 | |
May. 14 | Syros Pharmaceuticals, Inc. Agrees to Amend Its Loan Agreement with Oxford Finance LLC | CI |
Financials (USD)
Sales 2024 * | 500K | Sales 2025 * | 35.1M | Capitalization | 136M |
---|---|---|---|---|---|
Net income 2024 * | -91M | Net income 2025 * | -112M | EV / Sales 2024 * | 273 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 3.88 x |
P/E ratio 2024 * |
-2.25
x | P/E ratio 2025 * |
-1.93
x | Employees | 68 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.44% |
Latest transcript on Syros Pharmaceuticals, Inc.
1 day | +2.00% | ||
1 week | +2.62% | ||
1 month | -6.25% | ||
3 months | -34.19% | ||
6 months | +91.73% | ||
Current year | -34.53% |
Managers | Title | Age | Since |
---|---|---|---|
Conley Chee
CEO | Chief Executive Officer | 54 | 21-09-26 |
Nancy Simonian
CEO | Chief Executive Officer | 63 | 12-10-31 |
Jason Haas
DFI | Director of Finance/CFO | 56 | 21-10-11 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 56 | 17-06-11 | |
Tim Tyson
BRD | Director/Board Member | 71 | 22-09-15 |
Marsha Fanucci
BRD | Director/Board Member | 70 | 15-10-18 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 5.1 | +2.00% | 143,400 |
24-05-30 | 5 | -0.99% | 68,625 |
24-05-29 | 5.05 | +1.00% | 127,968 |
24-05-28 | 5 | +0.60% | 291,382 |
24-05-24 | 4.97 | -3.50% | 67,056 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.53% | 136M | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- SYRS Stock